Summary
The Southwest Oncology Group (SWOG) studied the response rate and toxicity of piroxantrone (150 mg/m2 q 21 days) in patients with advanced metastatic renal cell carcinoma. Among 32 eligible patients, there were no partial nor complete responses. There were two mixed responses. Significant white cell toxicity, anemia, nausea, and vomiting were observed. Mild or moderate degrees of fever, malaise, and stomatitis occurred. No significant cardiac toxicity was noted. Piroxantrone does not have significant activity as a single agent in advanced renal cell carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fry DW, Boritzki TJ, Besserer JA, Jackson RC:In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra [1,9-cd] pyrazol-6(2H)-ones (anthrapyrazoles). Biochem Pharmacol 34:3499–3508, 1985
Leopold WR, Nelson JM, Plowman J, Jackson RC: Anthrapyrazoles, a new class of intercalating agents with highlevel, broad spectrum activity against murine tumors. Cancer Res 45:5532–5539, 1985
Burchenal JH, Pancoast T, Elslager E: Anthrapyrazole and amsacrine analogs in mouse and human leukemiain vitro andin vivo. Proc Am Assoc Cancer Res 26:224, 1985
Sebolt JS, Havlick MJ, Hamelehle KL, Klohs WD, Steinkampf RW, Jackson RC: Establishment of adriamycin-resistant mammary adenocarcinoma 16/Cin vitro and its sensitivity to the anthrapyrazoles CI-942 and C-937. Proc Am Assoc Cancer Res 26:339, 1985
Hantel A, Donehower RC, Rowinsky EK, Vance E, Clarke BV, McGuire MP, Ettinger DS, Noe DA, Grochow LB: Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. Cancer Res 50:3284–3288, 1990
Ames MM, Loprinzi CL, Collins J, et al.: Phase I and clinical pharmacological evaluation of piroxantrone hydrochloride (oxantrazole). Cancer Res 50:3905–3909, 1990
Clarke BV, Harwood KV, Donehower R: Local toxicity of piroxantrone: an anthrapyrazole with irritant and vesicant properties similar to doxorubicin (letter). J Natl Cancer Instit 81:1331–1332, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Allen, A., Wolf, M., Crawford, E.D. et al. Phase II evaluation of piroxantrone in renal cell carcinoma. Invest New Drugs 10, 129–132 (1992). https://doi.org/10.1007/BF00873131
Issue Date:
DOI: https://doi.org/10.1007/BF00873131